

Seraseq[®] Lymphoma DNA Products

THE FIRST COMPREHENSIVE REFERENCE MATERIAL FOR NGS-BASED LYMPHOID ASSAY DEVELOPMENT, VALIDATION, AND ROUTINE QC USE

HIGHLIGHTS

HIGHLY MULTIPLEXED REFERENCE MATERIAL CONTAINING CLINICALLY-SIGNIFICANT VARIANTS PRIMARILY FOUND IN LYMPHOID TUMORS

FIRST-TO-MARKET REFERENCE STANDARD FOR LYMPHOMA DISEASES

HIGH-QUALITY MANUFACTURED REFERENCE MATERIAL; GUARANTEES CONSISTENT GROUND TRUTH

ABOUT LGC SERACARE

TRUSTED SUPPLIER TO THE DIAGNOSTIC TESTING INDUSTRY FOR OVER 30 YEARS

HIGH-QUALITY CONTROL PRODUCTS, RAW BIOLOGICAL MATERIALS, AND IMMUNOASSAY REAGENTS

INNOVATIVE TOOLS AND TECHNOLOGIES TO PROVIDE ASSURANCE IN DIAGNOSTIC ASSAY PERFORMANCE AND TEST RESULTS

FOR MORE INFORMATION, PLEASE VISIT OUR WEBSITE: WWW.SERACARE.COM

Lymphoma is cancer of the lymphatic system and represents about a third of all hematological disorders. In the US, ~5% of all cancers are diagnosed with this malignancy, which is the largest demography of blood cancers. While there are many subtypes of this disease, the two most notable are Hodgkin's Lymphoma (HL) and Non-Hodgkin's Lymphoma (NHL), which impact children as well as adults. According to the 2020 report of cancer diseases in the US by the National Cancer Institute (NCI), ~700,000 Americans are living with this disease, with ~80,000 newly diagnosed, and ~20,000 deaths.

To help clinical labs performing NGS-based lymphoid testing better develop, characterize, validate and routinely assess lymphoid diseases by NGS assays, LGC SeraCare has developed the Seraseq Lymphoma DNA Mutation Mix and Seraseq FFPE Lymphoma Reference Material, the first set of comprehensive lymphoid cancer NGS assay reference materials. These unique products include clinically important SNVs, INDELS and gene fusions important in lymphoma disease diagnosis and prognosis. Variants are present against a single well-characterized genomic background (GM24385) at clinically relevant allele frequencies, precisely quantitated by digital PCR assays.

Genes in the Seraseq Lymphoma DNA & FFPE Products

BCL2	MYD88	SF3B1	HSP90AA1-BCL6
BRAF	CXCR4	STAT3	CCND1-CDC42BPB
DNMT3A	NOTCH1	STAT5B	BIRC3-MALT1
EZH2	NOTCH2	TP53	MYC-IGH
IDH2	RHOA	NPM1-ALK	TBL1XR1-TP63

FEATURES AND BENEFITS

- Develop and validate Lymphoid-based NGS assays with confidence using a highly multiplexed reference material containing biomarkers important in Lymphoma cancers
- Provide robust sensitivity to detect clinically-relevant mutations at variant allele frequencies that establish and validate assay LoD claims
- Mutation targets are quantitated using highly sensitive digital PCR as well as a custom NGS assay
- All mutations are blended against GM24385 human genomic DNA as background 'wild-type' material.
- Available as both purified DNA mix and FFPE curls, for end-to-end assay workflow positive control
- Manufactured in GMP-compliant and ISO 13485-certified facilities

ORDERING INFORMATION

Product	Material No	Conc.	Fill Volume	Total Mass
Seraseq FFPE Lymphoma DNA Reference Material	0710-2202	1 FFPE curl/vial	10 µm	>100 ng*
Seraseq Lymphoma DNA Mutation Mix	0710-2203	25 ng/µl	15 µl	375 ng

* Based on Qiagen QIAamp DNA FFPE Tissue Kit and the Qubit dsDNA HS Assay.



Seraseq[®] is a registered trademark of SeraCare Life Sciences, Inc.
© 2021 SeraCare Life Sciences, Inc. All rights reserved.
MKT-00631-01